Abstract:Glucocerenrosidase1 (GBA1) mutations cause disruptions in endoplasmic reticulum (ER) and lysosome‐related proteostasis pathways in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons. Severe GBA1 mutations lead to increased ER stress (increased binding immunoglobulin protein (BiP) and protein disulfide isomerase (PDI) levels), total ubiquitination rates, and unfolded protein response (UPR). Defective chaperone‐mediated autophagy (decreased heat‐shock cognate protein 70 (HSC70) levels and decreased co‐localization of lysosomal‐associated membrane protein 2A (LAMP2A) and HSC70) is observed in iPSC‐derived dopaminergic neurons with mild homozygous GBA1 mutations. Decreased autophagosome formation (decreased microtubule‐associated protein light chain 3A (LC3) levels) is observed in iPSC‐derived dopaminergic neurons with homozygous N370S and D409H GBA1 mutations, while fusion defects (decreased lysosomal‐associated membrane protein 1 (LAMP1) and LC3 co‐localization) are observed in neurons with homozygous L444P GBA1 mutation. Severe GBA1 mutations trigger the accumulation of monomeric and oligomeric forms of α‐synuclein. GBA1 mutations increase the release of α‐synuclein from iPSC‐derived dopaminergic neurons. Glucocerebrosidase 1 (GBA1) mutations are the most important genetic risk factors for Parkinson's disease (PD). Clinically, mild (e.g., p.N370S) and severe (e.g., p.L444P and p.D409H) GBA1 mutations have different PD phenotypes, with differences in age at disease onset, progression, and the severity of motor and non‐motor symptoms. We hypothesize that GBA1 mutations cause the accumulation of α‐synuclein by affecting the cross‐talk between cellular protein degradation mechanisms, leading to neurodegeneration. Accordingly, we tested whether mild and severe GBA1 mutations differentially affect the degradation of α‐synuclein via the ubiquitin–proteasome system (UPS), chaperone‐mediated autophagy (CMA), and macroautophagy and differentially cause accumulation and/or release of α‐synuclein. Our results demonstrate that endoplasmic reticulum (ER) stress and total ubiquitination rates were significantly increased in cells with severe GBA1 mutations. CMA was found to be defective in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons with mild GBA1 mutations, but not in those with severe GBA1 mutations. When examining macroautophagy, we observed reduced formation of autophagosomes in cells with the N370S and D409H GBA1 mutations and impairments in autophagosome–lysosome fusion in cells with the L444P GBA1 mutation. Accordingly, severe GBA1 mutations were found to trigger the accumulation and release of oligomeric α‐synuclein in iPSC‐derived dopaminergic neurons, primarily as a result of increased ER stress and defective macroautophagy, while mild GBA1 mutations affected CMA, which is mainly responsible for the degradation of the monomeric form of α‐synuclein. Overall, our findings provide new insight into the molecular basis of the clinical variability in PD associated with different GBA1 mutations.

Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson's Disease: A Possible Factor Influencing Clinical Phenotype?

Mutations of glucocerebrosidase gene and susceptibility to Parkinson’s disease: An updated meta-analysis in a European population

The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA

The Degree of Cardiovascular Autonomic Dysfunction is not Different in GBA-Related and Idiopathic Parkinson's Disease Patients: A Case-Control Instrumental Evaluation

Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study

Glucocerebrosidase Mutations Influence the Natural History of Parkinson's Disease in a Community-Based Incident Cohort.

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation

Comparing GBA1-Parkinson's disease and idiopathic Parkinson's disease: α-Synuclein oligomers and synaptic density as biomarkers in the skin biopsy

Severe GBA1 variants drive the GBA-PD clinical phenotype: implications for counselling and clinical trials

Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers

Exposure Factors and Clinical Characteristics Associated with Parkinson’s Disease in GBA1 Variant Carriers: a Chinese GBA1-PD Intrafamilial Survey

Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease

Variant‐specific effects of GBA1 mutations on dopaminergic neuron proteostasis

Evaluation of the frequency of non-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1

Expanding the Spectrum of GBA1-Associated Neurodegenerative Diseases in an Italian Family

Peripheral Upregulation of Parkinson's Disease-Associated Genes Encoding α-Synuclein, β-Glucocerebrosidase, and Ceramide Glucosyltransferase in Major Depression

Lipidomic Profiling Reveals Shared and Distinct Pathological Signatures in Sporadic Parkinson's Disease and GBA Mutation Carriers: Implications for Disease Mechanisms

Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson's Disease

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies.